Ticker
KYMR
Analysis
Kymera Therapeutics, Inc. (KYMR) Stock Analysis
Kymera Therapeutics, Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysis connected to KYMR.
Kymera Therapeutics, Inc.
Kymera Therapeutics, Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysisconnected to KYMR.
Stock profile
Asset type
Stock
Market cap
$7.44B
Sector
Health Technology
Industry
Biotechnology
Currency
USD
Ticker listings
Kymera Therapeutics, Inc. may appear across multiple exchanges or ticker formats. 6ix consolidates those listings around the canonical analysis page for discovery.
- KYMR primary listing
Latest Kymera Therapeutics, Inc. news
Kymera Therapeutics Presents Phase 1 Data in Healthy Japanese Adults for KT-621, a First-in-Class Oral STAT6 Degrader, at the Japanese De...
Oral presentation at JDA features new data from the KT-621 Phase 1 study in healthy Japanese adults, with safety and PK/PD results consistent with previously reported KT-621 cli...
Kymera Therapeutics Announces First Participant Dosed in Phase 1 Trial of Oral IRAK4 Degrader, KT-485, and Milestone Achievement Under Sa...
Kymera Therapeutics Announces First Participant Dosed in Phase 1 Trial of Oral IRAK4 Degrader, KT-485, and Milestone Achievement Under Sanofi Collaboration
Kymera Therapeutics Presents New Preclinical Lupus Data for KT-579, First-in-Class, Oral IRF5 Degrader, at EULAR and FOCIS Congresses
KT-579 demonstrated consistent disease-modifying activity comparable or superior to approved and clinically active therapies in multiple preclinical lupus models KT-579 Phase 1 ...
Kymera Therapeutics to Participate in Fireside Chat at the Jefferies Global Healthcare Conference
Kymera Therapeutics to Participate in Fireside Chat at the Jefferies Global Healthcare Conference
Kymera Therapeutics Announces Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the Society for Investigative Dermatolog...
Late-breaking presentation at SID and featured presentation at the ATS Respiratory Innovation Summit highlight KT-621 BroADen Phase 1b clinical data and potential across Type 2 ...
Research sections
Valuation
Review valuation context for Kymera Therapeutics, Inc..
Future growth
Review future growth context for Kymera Therapeutics, Inc..
Past performance
Review past performance context for Kymera Therapeutics, Inc..
Financial health
Review financial health context for Kymera Therapeutics, Inc..
Dividend
Review dividend context for Kymera Therapeutics, Inc..
Management
Review management context for Kymera Therapeutics, Inc..
Ownership
Review ownership context for Kymera Therapeutics, Inc..
Other information
Review other information context for Kymera Therapeutics, Inc..
Community
Review community context for Kymera Therapeutics, Inc..